Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Large Increase in Short Interest

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 56,865 shares, an increase of 91.6% from the August 15th total of 29,679 shares. Based on an average daily trading volume, of 4,765,370 shares, the days-to-cover ratio is currently 0.0 days. Currently, 10.1% of the shares of the stock are short sold.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Wall Street Zen raised shares of Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a report on Sunday, August 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Jupiter Neurosciences

Several institutional investors have recently modified their holdings of JUNS. Vestor Capital LLC boosted its holdings in shares of Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares during the period. Yorkville Advisors Global LP bought a new position in shares of Jupiter Neurosciences during the 4th quarter valued at approximately $135,000. Finally, Allen Capital Group LLC purchased a new stake in Jupiter Neurosciences during the 4th quarter valued at $31,000.

Jupiter Neurosciences Price Performance

Shares of Jupiter Neurosciences stock traded down $0.40 during trading hours on Tuesday, reaching $3.01. The company’s stock had a trading volume of 57,792 shares, compared to its average volume of 382,749. The firm has a 50 day moving average price of $7.36 and a 200-day moving average price of $19.06. The stock has a market cap of $2.75 million, a P/E ratio of -0.16 and a beta of 1.81. Jupiter Neurosciences has a one year low of $2.88 and a one year high of $137.96.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings results on Friday, August 14th. The company reported ($5.06) EPS for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.40 million.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.